6th Nov 2015 08:10
LONDON (Alliance News) - Hutchison China MediTech Ltd on Thursday said its Hutchison MediPharma Ltd drug research and development subsidiary has started a phase 1 trial of sulfatinib in the US.
An investigation new drug application for the drug was submitted and cleared earlier this year and the first patient in the trial was dosed this week, Hutchison said.
Sulfatinib is a cancer treatment which selectively inhibits tyrosine kinase activity associated with tumour growth.
Shares in Hutchison China were up 2.3% just after the open on Friday at 2,775.00 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Hutchmed